My watch list  

[In Depth] As Ebola wanes, trials jockey for patients

The Ebola epidemic in West Africa has caused enormous suffering, but scientists also see it as a chance to test experimental therapies that could save lives in the future. With declining case numbers, however, it is becoming less likely that all the drug tests will reach a conclusion. Now, scientists are debating whether some trials should be stopped so that tests of more promising therapies that have only now become available have a better chance of reaching a conclusion. An expert panel at the World Health Organization has given ZMapp and TKM-Ebola highest priority but in a recent meeting did not call for ongoing studies of favipiravir and convalescent blood to be stopped. The experts did convince a group of Italian doctors to test ZMapp instead of the heart drug amiodarone and criticized an interferon trial that has now started in Guinea. Author: Kai Kupferschmidt

Authors:   Kai Kupferschmidt
Journal:   Science
Volume:   348
edition:   6230
Year:   2015
Pages:   20
DOI:   10.1126/science.348.6230.20
Publication date:   03-Apr-2015
Facts, background information, dossiers
More about Science International / AAAS
  • Publications

    Random number generators go public

    On 10 July, researchers in Chile will unveil an online public random number service. Later in July, the U.S. National Institute of Standards and Technology (NIST) will launch its Randomness Beacon as a permanent service, upgrading a pilot program that began in 2013. Brazil, too, is planning ... more

    When the cure kills—CBD limits biodiversity research

    The Convention on Biological Diversity (CBD) commits its 196 nation parties to conserve biological diversity, use its components sustainably, and share fairly and equitably the benefits from the utilization of genetic resources. The last of these objectives was further codified in the Conve ... more

    See-through solar cells could power offices

    Solar windows turn some of the light shining through into electricity. They've been on the market for years. But many of these windows absorb some visible light, leaving them with a reddish or brownish hue, a trait frowned on by architects. Now, new versions are on the way that absorb invis ... more

  • News

    Merck Named a Top Employer by Science Magazine

    Merck announced it was ranked fourth among biotechnology and pharmaceutical companies worldwide by Science magazine, a leading peer-reviewed international scientific publication. This ranking marks the fourth year in a row Merck was named one of the top 20 employers in the healthcare and li ... more

    Merck Named as Top Employer by Science Magazine

    Merck announced it was named number 11 among the top 20 employers in the global biopharmaceutical industry by Science magazine, a leading peer-reviewed international scientific publication. This is the third year in a row that Merck, including EMD Serono in the United States, has been named ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE